Skip to main content
Clinical Trials/NCT00889031
NCT00889031CompletedNot Applicable

Protocol to Obtain Blood Samples for Leukemia Research

Dartmouth-Hitchcock Medical Center1 site in 1 country187 target enrollmentStarted: April 2009Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
187
Locations
1
Primary Endpoint
To determine the frequency with which CLL cells incubated ex vivo with vincristine undergo rapid interphase apoptosis.

Study Overview

Brief Summary

The purpose of this study is to collect a blood sample in patients with Chronic Lymphocytic Leukemia (CLL).

Detailed Description

The blood sample will be used in the laboratory to perform studies focusing on Chronic Lymphocytic Leukemia (CLL).

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients undergoing routine blood draws as part of their ongoing follow-up for Chronic Lymphocytic Leukemia (CLL) at the Norris Cotton Cancer Center of DHMC.

Exclusion Criteria

  • Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for CLL or other disease process within the past 6 months are excluded. Use of intravenous immunoglobulin (IVIg) is not a reason for exclusion.

Outcomes

Primary Outcomes

To determine the frequency with which CLL cells incubated ex vivo with vincristine undergo rapid interphase apoptosis.

Time Frame: 2 Years

Secondary Outcomes

  • To determine whether suppression or inhibition of BCL2 family members can acutely sensitize CLL cells to vincristine.(2 Years)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Christopher H. Lowrey

Professor of Medicine and of Pharmacology and Toxicology

Dartmouth-Hitchcock Medical Center

Study Sites (1)

Loading locations...

Similar Trials